- Home
- BEN vs EXEL Comparison
BEN vs EXEL Comparison
Compare BEN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEN
- EXEL
- Stock Information
- Founded
- BEN 1947
- EXEL 1994
- Country
- BEN United States
- EXEL United States
- Employees
- BEN N/A
- EXEL N/A
- Industry
- BEN Investment Managers
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BEN Finance
- EXEL Health Care
- Exchange
- BEN Nasdaq
- EXEL Nasdaq
- Market Cap
- BEN 9.8B
- EXEL 9.8B
- IPO Year
- BEN N/A
- EXEL 2000
- Fundamental
- Price
- BEN $20.84
- EXEL $36.50
- Analyst Decision
- BEN Sell
- EXEL Buy
- Analyst Count
- BEN 12
- EXEL 18
- Target Price
- BEN $19.46
- EXEL $37.59
- AVG Volume (30 Days)
- BEN 4.5M
- EXEL 2.3M
- Earning Date
- BEN 05-02-2025
- EXEL 05-13-2025
- Dividend Yield
- BEN 6.14%
- EXEL N/A
- EPS Growth
- BEN N/A
- EXEL 170.77
- EPS
- BEN 0.69
- EXEL 1.76
- Revenue
- BEN $8,697,100,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- BEN N/A
- EXEL $5.78
- Revenue Next Year
- BEN $0.60
- EXEL $10.94
- P/E Ratio
- BEN $30.09
- EXEL $20.74
- Revenue Growth
- BEN 7.38
- EXEL 18.50
- 52 Week Low
- BEN $16.25
- EXEL $20.14
- 52 Week High
- BEN $24.86
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- BEN 70.67
- EXEL 45.67
- Support Level
- BEN $19.79
- EXEL $35.34
- Resistance Level
- BEN $20.31
- EXEL $40.26
- Average True Range (ATR)
- BEN 0.53
- EXEL 1.21
- MACD
- BEN 0.32
- EXEL -0.09
- Stochastic Oscillator
- BEN 90.72
- EXEL 29.79
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of February 2025, Franklin had $1.577 trillion in managed assets, composed primarily of equity (39%), fixed-income (30%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (4%). Distribution tends to be weighted not quite equally between retail investors (54% of AUM) and institutional accounts (43%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 30% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.